Beam Therapeutics (BEAM) Other Non-Current Liabilities (2019 - 2026)

Beam Therapeutics (BEAM) has reported Other Non-Current Liabilities for 8 consecutive years, with $5.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 14.11% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $5.4 million (down 14.11% YoY), while the FY2025 annual figure was $173000.0, down 84.7% from the prior year.
• Other Non-Current Liabilities rose to $5.4 million in Q1 2026 per BEAM's latest filing, from $173000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $12.8 million in Q1 2023 and bottomed at $173000.0 in Q4 2025.
• Historically, Other Non-Current Liabilities has averaged $4.0 million across 5 years, with a median of $2.7 million in 2023.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities plunged 99.19% — and 2023, when it surged 3371.48%.
• Beam Therapeutics' Other Non-Current Liabilities stood at $1.4 million in 2022, then jumped by 97.61% to $2.7 million in 2023, then slumped by 58.46% to $1.1 million in 2024, then sank by 84.7% to $173000.0 in 2025, then soared by 3049.71% to $5.4 million in 2026.
• Business Quant data shows BEAM's Other Non-Current Liabilities at $5.4 million in Q1 2026, $173000.0 in Q4 2025, and $266000.0 in Q3 2025.